RT Journal Article
SR Electronic
T1 Unrecognized introductions of SARS-CoV-2 into the state of Georgia shaped the early epidemic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.19.21262615
DO 10.1101/2021.09.19.21262615
A1 Babiker, Ahmed
A1 Martin, Michael A.
A1 Marvil, Charles E.
A1 Bellman, Stephanie
A1 Petit, Robert A.
A1 Bradley, Heath L.
A1 Stittleburg, Victoria D.
A1 Ingersoll, Jessica M.
A1 Kraft, Colleen S.
A1 Read, Timothy D.
A1 Waggoner, Jesse J.
A1 Koelle, Katia
A1 Piantadosi, Anne
YR 2021
UL http://medrxiv.org/content/early/2021/09/25/2021.09.19.21262615.abstract
AB In early 2020, as SARS-CoV-2 diagnostic and surveillance responses ramped up, attention focused primarily on returning international travelers. Here, we build on existing studies characterizing early patterns of SARS-CoV-2 spread within the U.S. by analyzing detailed clinical, molecular, and viral genomic data from the state of Georgia through March 2020. We find evidence for multiple early introductions into Georgia, despite relatively sparse sampling. Most sampled sequences likely stemmed from a single introduction from Asia at least two weeks prior to the state’s first detected infection. Our analysis of sequences from domestic travelers demonstrates widespread circulation of closely-related viruses in multiple U.S. states by the end of March 2020. Our findings indicate that the early attention directed towards identifying SARS-CoV-2 in returning international travelers may have led to a failure to recognize locally circulating infections for several weeks, and points towards a critical need for rapid and broadly-targeted surveillance efforts in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the CDC contract 75D30121C10084 under BAA ERR 20-15-2997 the Pediatric Research Alliance Center for Childhood Infections and Vaccines and Childrens Healthcare of Atlanta and the Emory WHSC COVID-19 Urgent Research Engagement (CURE) Center made possible by generous philanthropic support from the O. Wayne Rollins Foundation and the William Randolph Hearst Foundation. AP is supported by NIH K08 AI139348. The Yerkes NHP Genomics Core is supported in part by NIH P51 OD011132 and sequence data was acquired on an Illumina NovaSeq6000 funded by NIH S10 OD 026799. Sample collection was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Emory University institutional review boardAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPublicly-available SARS-CoV-2 sequences from Georgia were generously contributed by Mayo Clinic Laboratories, Quest Diagnostics, and the U.S. Air Force School of Aerospace Medicine. We gratefully acknowledge the authors from the originating laboratories responsible for obtaining the specimens, as well as the submitting laboratories where the genome data were generated and shared via GISAID, on which this research is based (Supplementary Table 10). All Submitters of data may be contacted directly via www.gisaid.org.All the data will be publicly released upon publication.